CardioSert
Advanced Tools for Interventional Cardiologists Performing PCI Procedures
Company Overview
Snapshot
Founded in March 2012 by Avrahan Shkalim and Noam Peleg, CardioSert operates with 1–10 employees. The company has completed 2 funding rounds with 3 investors. In May 2018, CardioSert was acquired by Microbot Medical.
Business overview
CardioSert develops advanced tools for interventional cardiologists, focusing on percutaneous coronary intervention (PCI) procedures. The company's core products include a proprietary guide wire designed to navigate complex lesions like chronic total occlusion (CTO) and a pressure guide wire for measuring fractional flow reserve (FFR). These technologies aim to enhance the safety and efficiency of arterial recanalization and blockage assessment, serving the medical devices and cardiology sectors within the broader Health Tech & Life Sciences industry.
Strategic signal
In May 2018, Microbot Medical completed its acquisition of CardioSert's novel technology. This acquisition signifies a strategic move by Microbot Medical to integrate CardioSert's innovative CTO and FFR tools, including its R&D information, technical know-how, and intellectual property, into its portfolio. For investors, this indicates a validation of CardioSert's technology and its potential to impact the interventional cardiology market through a larger corporate entity.
Log in to access full profile ›Company Intelligence Q&A
- What is CardioSert's primary focus?
- CardioSert develops advanced tools specifically for interventional cardiologists to use during percutaneous coronary intervention (PCI) procedures.
- When was CardioSert acquired?
- CardioSert was acquired by Microbot Medical in May 2018.
- What technology did Microbot Medical acquire from CardioSert?
- Microbot Medical acquired CardioSert's novel patent-protected technology, including its innovative CTO tool and FFR tool, along with R&D information, technical know-how, and intellectual property.
- Which investors participated in CardioSert's July 2014 funding round?
- In July 2014, CardioSert received funding from Magna Capital Partners and Medvest.